Le Lézard
Classified in: Health, Science and technology, Business

Global Cord Blood Corporation Announces Results of 2019 Annual General Meeting

HONG KONG, Dec. 5, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2019 Annual General Meeting, which was held on December 5, 2019, in Hong Kong S.A.R., China.

At the Annual General Meeting, shareholders

About Global Cord Blood Corporation

Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and no new licenses will be granted before 2020 in addition to the seven licenses authorized as of today. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company's website at http://www.globalcordbloodcorp.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the U.S. Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

Global Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@globalcordbloodcorp.com

ICR, Inc.
Mr. William Zima
Tel: (+86) 10-6583-7511 (China) or (+1) 646-405-5185 (U.S.)
Email: william.zima@icrinc.com

SOURCE Global Cord Blood Corporation

These press releases may also interest you

at 06:33
For the second year in a row, users of the free, award-winning healthcare cost transparency website fairhealthconsumer.org made "MRI" the top searched medical term and "root canal" the top searched dental term when using the site's cost lookup tools....

at 06:32
At the end of 2019, exocad GmbH announced the worldwide availability of the new software version DentalCAD 2.4 Plovdiv - after Matera in March 2019, the second comprehensive release of the year. One of the highlights is the significantly enhanced...

at 06:30
The "2020 Global Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing: US, Europe, Japan - Supplier Shares and Segment Forecasts by Country, Emerging Technologies, Competitive Strategies" report has been added to...

at 06:30
Alma, Inc., announces the North American release of Opustm, a new modern aesthetic platform featuring the company's proprietary high-frequency unipolar radio-frequency technology, Opus Plasmatm. As the first-of-its-kind fractional plasma technology,...

at 06:25
The "2020 UK Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing: Supplier Shares by Country and Segment Forecasts, Emerging Technologies, Competitive Strategies" report has been added to ResearchAndMarkets.com's offering....

at 06:08
The global mHealth market size is expected to reach USD 293.29 billion by 2026, exhibiting a CAGR of 29.1% during the forecast period. The increasing penetration of smartphones and smart devices will boost the mHealth market trends during the...

News published on 5 december 2019 at 08:30 and distributed by: